Suppr超能文献

肥胖儿科患者在心脏导管室的肝素用药剂量。

Heparin dosing in obese pediatric patients in the cardiac catheterization laboratory.

机构信息

Department of Pharmacy, Texas Children's Hospital, Houston, TX, USA.

出版信息

Ann Pharmacother. 2011 Jul;45(7-8):876-80. doi: 10.1345/aph.1Q090. Epub 2011 Jul 20.

Abstract

BACKGROUND

Unfractionated heparin (UFH) dosing may need to be adjusted when used in obese patients. The prevalence of pediatric obesity is increasing and, to our knowledge, no data exist to determine the effect of obesity on UFH therapy in children.

OBJECTIVE

To determine whether obese pediatric patients who receive a weight-based dose of UFH in the cardiac catheterization laboratory exhibit an enhanced response compared with those of normal body habitus.

METHODS

The records of pediatric patients who underwent a cardiac catheterization procedure from September 2006 to September 2010 at Texas Children's Hospital were reviewed. Patients were included if they had received a bolus dose of UFH during their procedure, and had pre- and post-UFH bolus activated clotting time (ACT) values determined. Patients were identified as obese if their body mass index (BMI) was at the 95th percentile or more for age and sex and were matched by age, sex, and catheterization procedure to a control group of patients with a BMI lower than the 95th percentile. Differences in demographic, UFH, and ACT variables were compared between obese and nonobese paired groups.

RESULTS

Seventy-eight patients (39 obese) met study criteria; 46 (58.9%) patients were male. The primary catheterization procedure was radiofrequency ablation (n = 32). There was no statistically significant difference in the mean (SD) dose per kilogram of UFH administered (72.3 [24.9] vs 63.6 [23.6] units/kg; p = 0.12) and no statistically significant difference in the time after the UFH bolus that the ACT was measured (52 [26] vs 56 [26] minutes; p = 0.59) between the 2 groups. No statistically significant difference was noted in the percent change in ACT after UFH bolus in obese compared to nonobese pediatric patients (196% [106] vs 165% [97]; p = 0.17).

CONCLUSIONS

No significant difference in response to UFH was identified in obese pediatric patients compared to nonobese pediatric patients as measured by ACT in the cardiac catheterization laboratory.

摘要

背景

在肥胖患者中使用未分级肝素(UFH)时,可能需要调整剂量。儿科肥胖的患病率正在增加,据我们所知,尚无数据确定肥胖对儿童 UFH 治疗的影响。

目的

确定在心脏导管插入术实验室接受 UFH 体重剂量的肥胖儿科患者与体型正常的患者相比是否表现出增强的反应。

方法

回顾 2006 年 9 月至 2010 年 9 月在德克萨斯儿童医院进行心脏导管插入术的儿科患者的记录。如果患者在手术过程中接受了 UFH 推注剂量,并且已经确定了 UFH 推注前后的激活凝血时间(ACT)值,则将其纳入研究。如果患者的体重指数(BMI)为年龄和性别第 95 百分位或更高,则将其确定为肥胖患者,并按年龄、性别和导管插入程序与 BMI 低于第 95 百分位的对照组患者相匹配。比较肥胖和非肥胖配对组之间的人口统计学、UFH 和 ACT 变量的差异。

结果

78 名患者(39 名肥胖)符合研究标准;46 名(58.9%)患者为男性。主要的导管插入术为射频消融术(n = 32)。给予的 UFH 每公斤剂量的平均值(SD)(72.3[24.9]与 63.6[23.6]单位/kg;p = 0.12)和测量 ACT 后 UFH 推注后的时间(52[26]与 56[26]分钟;p = 0.59)在两组之间无统计学差异。肥胖与非肥胖儿科患者相比,UFH 推注后 ACT 的百分比变化无统计学差异(196%[106]与 165%[97];p = 0.17)。

结论

与非肥胖儿科患者相比,在心脏导管插入术实验室中,ACT 并未发现肥胖儿科患者对 UFH 的反应有显著差异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验